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Study Objective: This study describes menstrual dysfunction and treatment among 
adolescent and young adult (AYA) females with congenital heart disease (CHD). 
Design: Data collected from a one-time survey completed by AYA females (and mothers 
if AYA unable). 
Setting: Participants were recruited from pediatric cardiology clinics. 
Participants: Female AYA with CHD, ages 14-21 (N=114). 
Interventions: None. 
Main Outcome Measures: The questionnaire assessed sexual and reproductive health 
(SRH) concerns, behaviors and management. Outcome measures were self-reported 
menstrual complaints, use of over the counter (OTC) pain relief medicines for 
dysmenorrhea, reported visits with a clinician for a menstrual problem and reported use 
of hormones for menstrual problems or birth control. 
Results: Mean age was 17.0 years (SD=2.2). A majority (83%) reported one or more 
menstrual complaints: 67.5% cramping, 42.1% irregular menses, 46.5% heavy periods, 
and 88% reported any history of taking OTC for pain relief. Increased menstrual 
complaints were not associated with level of cardiac complexity, reported transplant, or 
reported use of hormonal contraception. However, 32% of participants reported use of 
hormonal contraception for menstrual dysfunction; combined oral contraceptive pills 





Conclusions: A large majority of AYA females with CHD reported menstrual dysfunction. 
Use of OTC medication for menstrual pain and inappropriate use of estrogen creates 
concerns that menstrual disorders may be unaddressed or addressed inappropriately. 
Thus, gynecological needs of adolescents with CHD may need to be specifically 
targeted by providers that feel comfortable with this population and their complex needs. 
 






Over 85% of adolescents and young adults (AYA) with congenital heart disease 
(CHD) are living well into adulthood and are in need of reproductive health.1 AYA 
females with CHD have specific contraception needs due to increased risk of 
thromboembolic events and/or fatality, as well as complications with unintended 
pregnancy.2-4 Use of certain medications – both over the counter (OTC) and prescribed 
– for menstrual problems need to be monitored due to potential adverse events 
associated with the CHD condition or transplantation. Sexual activity is rarely assessed 
in women with CHD; data suggests that AYA with CHD have inadequate knowledge of 
contraception and that few have discussed sexual and reproductive health (SRH) issues 
with their cardiologists or any other health professional.5-10 These findings raise the 
need for interventions that address these issues.11,12  
The exact reproductive health needs of adolescents with CHD, including those 
that have been transplanted due to a CHD related lesion, are not well described despite 
the literature continuing to report poor provisions of services particularly in the areas of 
family planning, counseling about pregnancy, and treatment for menstrual dysfunction, 
including dysmenorrhea, menorrhagia and irregular menses. A few studies have 
reported increased rates of menstrual dysfunction, including delayed menarche, 
anovulatory cycles and dysmenorrhea in AYA females with CHD.5-7,9  Others have 
reported increased rates of menorrhagia as a significant complication in AYA females 
using anticoagulants.8  As with other chronic diseases, the reproductive health needs 
may be more complex and unique, requiring a better understanding not only of the CHD 




In attempts to better understand more current menstrual related needs, this study 
examines the self-reported menstrual dysfunction among AYA females with CHD and 
treatment with OTC and provider-prescribed medications, including hormonal 
contraception. Secondary analysis examined the associations of menstrual dysfunction 
with OTC and hormonal treatments, history of sexual activity, transplantation, and 
cardiac complexity. 
 
Materials and Methods 
Study Participants.  
This study was part of a larger project that recruited adolescent females with 
CHD, as well as their mother or female guardian, from two university associated 
pediatric cardiology clinics from September 2015 to August 2018. Eligible adolescents 
between the ages of 14 and 21 years old, and the mother or female guardian of eligible 
adolescents, were simultaneously recruited at their regularly scheduled appointments. 
Recruitment of only female guardians was related to survey items that examined 
specific daughter-mother reproductive conversations (not used in this study). Literature 
suggests that conversations surrounding puberty and sexuality occur more commonly 
amongst adolescent females and their mothers, rather than their fathers.13-15  Informed 
assent and/or consent were obtained from interested participants and their 
mother/guardian. Parents provided permission for adolescents who were 17 years and 
younger, and young adults aged 18 years or older provided their own informed consent. 




survey autonomously, the guardian was asked in all cases if their daughter had the 
ability to participate in a web-based survey at the time of recruitment. If the guardian did 
not feel their daughter was capable of completing a survey, the guardian was offered 
the opportunity to participate alone. The researcher was present during completion of 
the questionnaires to ensure independence of responses. If both patient and guardian 
completed the survey, patient data was used for this analysis due to assumed greater 
accuracy with regards to sexual activity, hormone use, and SRH data. However, in the 
cases where adolescents did not complete a survey, the parent or guardian survey was 
used in order to assess menstrual disorders among the entire cohort.  
 Consented adolescents and/or their parent/guardian independently completed a 
one-time electronic questionnaire assessing various reproductive issues (Table 1). 
Participants answered yes/no to reports of cramping, irregular menses, and/or heavy 
periods. Menstrual problems were not defined, and were left to the participant’s own 
interpretation. Participants reported if they had ever seen a clinician for a menstrual 
problem and were asked about use of OTC medication for pain (menstrual cramps).  All 
of those queried were asked about use of any hormonal contraception for a menstrual 
problem or puberty. If a participant reported use of hormonal contraception, they were 
asked to indicate which method(s) they used from a list provided and if use was in the 
past, currently using, or never used. Only the adolescent survey asked about sexual 
activity (yes/no) as well as if the use of this hormonal contraception was to prevent 
pregnancy. Cumulative use of hormonal methods for the entire cohort was examined by 




The study cardiologist completed a clinician-generated survey for each 
participant by accessing the patient’s Electronic Medical Record (EMR) to report the 
adolescent’s CHD lesion(s) and current contraindications to hormonal contraceptive 
methods. Prior to enrollment, a predefined list of contraindications to birth control was 
compiled based on current literature, national and international risk criteria, and /or 
consensus guidelines for congenital cardiac lesions.4-6,16-20 Contraindications to 
estrogen included adolescent women with functional class III and IV heart failure, 
cyanosis, Eisenmenger syndrome, history of thromboembolism, non-repaired 
coarctation and pulmonary arterial hypertension.  For analysis, cardiac lesions were 
further classified by the study cardiologist as simple, moderate, complex or transplanted 
based on American College of Cardiology’s criteria.21 Participants and parents were 
asked to report their (or their daughter’s) level of disability on the surveys as none, mild, 
mild to moderate, moderate to significant, or significant with regards to level of 
assistance and independence with responsibilities and activities of daily living. These 
were grouped into none, mild to moderate and moderate to significant for data analysis. 
Statistical Procedure.  
Data was analyzed using Statistical Package for Social Sciences (version 26). 
Descriptive statistics include population characteristics, which are reported as 
percentages. All adolescents that had reported (or parents who reported for their 
daughter) having experienced menarche were included in this analysis. Bivariate 
analyses (chi-squared and t-tests) were used to examine factors associated with 





A total of 95 adolescent/parent pairs and 15 individual female AYA, and 16 
individual parents were enrolled to participate in this study. For this analysis, 1 
participant was excluded due to age, 6 due to incomplete surveys, and 4 who had not 
yet achieved menarche. Fifteen parental surveys were used (one excluded due to no 
menarche) without an AYA survey due to disability (Figure 1). Thus, our final sample 
consisted of 114: 99 AYA and 15 parent surveys. 
The average age of the AYA was 17.0 (range 14 to 21) years at time of 
enrollment and 12.5 (range 8 to 17) years at menarche. Baseline demographic 
information is included in Table 2. A majority reported having no disabilities (N=80, 
71%), 22 (19.5%) participants reported mild to moderate disability, 11 (9.7%) parents 
reported moderate to significant disability, and 1 participant did not answer the question 
about disability. Forty-six (40.4%) had a single cardiac lesion reported by the clinician, 
and 68 (59.6%) had more than one cardiac lesion. Twenty-eight (24.6%) were classified 
based on their current lesion as having simple CHD lesions, 46 (40.4%) had moderate, 
33 (28.9%) had complex lesions, and 7 (6.1%) were transplanted. 
 Menstrual dysfunction was prevalent (Table 1). Ninety-five participants (83.3%) 
had at least one menstrual complaint, 77 (67.5%) reported cramping, 48 (42.1%) 
irregular menses, and 53 (46.5%) heavy menses (Figure 2). Twenty-nine percent of all 
participants (N= 33) reported seeing a clinician for some type of menstrual dysfunction. 
About a quarter of those who had menstrual problems or saw a clinician for a menstrual 
problem had a contraindication to estrogen (Figure 2). All participants with confirmed 
transplanted hearts (n=7) reported at least one menstrual complaint as well. There was 




problem (p=.78) or with level of disability (p=.97). Complexity of cardiac lesion was not 
associated with increased reports of menstrual dysfunction (p=.69). However, higher 
lesion complexity was associated with increased likelihood of seeing a clinician for 
menstrual dysfunction (p =.03). Of those who reported heavy bleeding (N=53), only 4 
reported current Warfarin use. Ninety-five participants – including 4 out of 7 AYA with 
cardiac transplant – reported use OTC medication for menstrual related pain.  
 Cumulative use of hormones was assessed in the cohort. Assessing combined 
responses by adolescent and parents to all questions (past use, current use) and use 
for any purpose, a total of 38 patients (33%) had been prescribed hormonal 
contraception (any method) at some point.  The most frequently reported hormonal 
method was COC pills; 25 (22%) were using COC pills currently or had used in the past. 
Ten (7%) reported past or current use of depo-medroxyprogesterone; 2 reported use of 
a progestin IUD, and 10 reported implant use. Only 1 patient reported use of the patch 
in the past.  No association was found between self-reported menstrual dysfunction and 
reports of use of any hormonal contraception (p =.929).  
With regards to current use (N=26) of hormonal methods, a majority (N=14) were 
currently using combined oral contraceptive pills (COCs): 3 (3%) by parental reports, 2 
(2%) by self-report for both menstrual problem and birth control, 9 (8%) for menstrual 
problem only. This current use of COCs was examined due to 19 (16.7%) participants 
carrying a contraindication to estrogen.  One of these participants with contraindications 
reported current COC use, and 1 reported use in the past.   
 Thirty-four of the 99 (34%) adolescent participants self-reported a history of 




dysfunction was reported by 27 of the 34 who reported sexual activity, which did not 
differ significantly from the entire study sample (79% vs. 83% respectively, p=.51). Of 
these 34 sexually active adolescents, 23 (68%) reported having been or currently on 
prescribed contraception. Two participants denied sexual activity but endorsed using 
any birth control method to prevent a pregnancy. 
 
Discussion  
Menstrual dysfunction occurs frequently (83.3%) in AYA females with CHD, 
though relatively few reported receiving clinical treatment from a provider (28.9%). 
Based on the average age of menarche, delays in puberty were probably infrequent. 
Despite seeing a high level of reports of one or more menstrual complaints, 
dysmenorrhea was the most common complaint among the cohort, but the prevalence 
is consistent with that reported in the general population.22 Reports of heavy menses 
were more prevalent than that seen in the general population, whereas irregular 
menses was similar to the general population.22-24 Lesion complexity was not 
associated with more menstrual dysfunction. However, higher lesion complexity was 
associated with higher likelihood of medical intervention. This may indicate that 
increased interaction with medical providers leads to more direct referral for treatment. 
 Interestingly, those who reported a cardiac transplant all experienced menstrual 
dysfunction and over half reported the use of OTC medication.  Due to the way this was 
asked in the survey, we could not differentiate non-steroidal anti-inflammatory drugs 
(NSAIDs) from other medications (such as acetaminophen).  This is potentially 




to risk of renal toxicity associated with use of transplant-specific medication.25 This may 
raise the need to ask specifically about menstrual cramping in transplanted patients to 
assure that they are not accessing OTC medications that include NSAIDs. 
Use of warfarin by adolescents has been associated with menorrhagia rates 
twice that of the general population.26,27 Although this study had high numbers of self-
reported heavy menses, no association with warfarin was found. Warfarin use was not 
that common and this may reflect more use of other anticoagulant therapies (i.e. direct 
oral anticoagulants) which was not specifically asked by the survey, nor have direct oral 
anticoagulants been associated with heavy menses.28,29  However, use of 
anticoagulants, of any type, may have played a role in the higher prevalence of heavy 
bleeding reported in this population. 
At least 10% of the participants who reported any of the three reported menstrual 
complaints had contraindications to estrogen. In addition, 2 participants who were 
prescribed estrogen-containing contraception had a contraindication to estrogen. 
Previous studies have shown that providers prescribe estrogen-containing 
contraception to reproductive-aged patients with contraindications.30,31 Given the 
potential for estrogen contraindications in AYA with CHD, and the fact that 5% (2 of 38) 
had reported use of this medication in the face of a contraindication, there is a strong 
need for provider education when addressing reproductive needs of this population. 
 Finally, though the overall numbers were small, many sexually active 
adolescents were not prescribed contraception, raising concerns for pregnancy 
complications or unintended pregnancy. At times patients may already be sexually 




complaints.  Thus, it is important that providers do query, confidentially, all reasons for 
hormonal contraception to ensure proper response to the health care needs of the 
patient. While many factors may contribute to contraceptive choice, all providers may 
benefit from education and training of more effective, non-estrogen containing methods 
of contraception, such as IUDs and implants. 
A limitation of our study was that results were based on self-reported or 
maternal-reported survey data and would benefit from clinical clarification through 
detailed history. We recognize this is a convenience sample; however, attempts were 
made to recruit any adolescent who qualified during a clinic visit when study researcher 
could be present. In addition, the study was predominantly Caucasian females, which 
may limit generalizability to other ethnic or racial groups. Nonetheless, this study 
represents the largest cohort of AYA females with CHD with menstrual related data.   
 The large number of complaints about menstrual dysfunction but little use of 
hormonal medication, inappropriate use of estrogen, and potential overuse of OTC 
medication indicates menstrual dysfunction is inadequately addressed in this 
population.  The lack of reported hormonal contraception use among those who have 
previously been sexually active indicates contraceptive needs are not being adequately 
addressed.  As medical treatments continue to expand longevity of women with CHD, 
we predict the need to address these reproductive issues will also increase.13  A 
precision health approach would benefit this population with their unique and complex 
needs. Next steps would include further education for primary care providers and 
cardiologist to assist in identifying reproductive needs for direct intervention or referral to 




CHD. Cardiologists may consider collaborating with reproductive health specialists such 
as gynecologists and adolescent health providers to best provide for these patients. 
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Table 1. Survey questions and responses. 
Reproductive Health Questions (N=114) Yes 
N (%) 
Have you had any problems with the following menstrual (period) related issues: 
     Cramping? 77 (68) 
     Irregular periods? 48 (42) 
     Heavy periods 53 (47) 
Have you (or your daughter) seen a clinician (doctor or nurse) for a 
menstrual problem? 
33 (29) 
Have you (or your daughter) taken a medicine for pain relief that you 
can get over the counter such as acetaminophen, ibuprofen, naproxen 
or brand name medications (such as Tylenol®, Midol®, Advil®, 
Aleve®)? 
95 (83) 
Have you (or your daughter) taken any hormones (birth control pills, 
estrogen, progestin, etc.) for a menstrual problem or for puberty? 
38 (33) 
Have you ever had sex with a male (penis in the vagina)?*  34 (34) 
Have you ever used or currently using any birth control methods to 
prevent a pregnancy?*  
19 (19) 
Have you (Has your daughter) ever seen a health provider for any of the below reasons? 
     Menstrual suppression (stop my periods) for cramps 11 (9.6) 
     Menstrual suppression (stop my periods) for heavy bleeding 15 (13.2) 
     Birth control to help prevent a pregnancy 16 (14.0) 
     I (She) was pregnant 3 (2.6) 
     I have not seen a health provider for these conditions 80 (70.2) 
*N=99, question not asked of parents. 
Table 2. Participants demographics and CHD lesions (N=114). 
 Mean (SD) or N (%) 
Age  (years, range 14-21) 17.0 ± 2.2 
Race (White) 99 (88%) 
Age at menarche 12.5 ± 1.7 
Ever had sex (yes)* 34 (34%) 
CHD Complexity** 
Simple 28 (24.6%) 
Moderate 46 (40.4%) 
Complex 33 (28.9%) 
          Confirmed transplant 7 (6.1%) 
*N=99, question not asked of parents 
**Complexity determined by American College of Cardiology 
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No CI to estrogen Contraindications to estrogen
Figure 1. Participant Enrollment Diagram
N=11 Excluded
6 Incomplete surveys
4 Not achieved menarche
1 Too young
N=1 Excluded due 
to no menarche













Parents not included for 
this study unless 
adolescent unable to 
answer
